Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the ...
Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS ...
Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...
Less than two months after an accelerated approval from the FDA, a drug combination featuring Pfizer’s Braftovi has turned in ...
Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall ...
Topline data on a combo including Pfizer’s kinase inhibitor Braftovi point to improved progression-free survival and pave the ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
1d
Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...
Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...
Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...
Pfizer’s Braftovi combo regimen helped prolong the lives of certain patients with previously untreated colorectal cancer, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback